Looking for Steady Passive Income? This S&P 500 Dividend Stock Pays You Monthly.

Healthpeak Properties shares have risen 27.5% in 2026 after Q1 EPS of $0.28 beat the $0.06 forecast by roughly 367% and revenue of $739 million exceeded the $687 million consensus by 7.5%. Management raised 2026 FFO guidance twice, most recently to $1.73-$1.77 per share after strong Q2 results, while the REIT offers a $1.22 annualized dividend yielding about 6% at $20.42. Key risks are rising rates, which increase financing costs and make bonds more competitive, although aging-population demand for healthcare and senior housing remains a structural tailwind.

Analysis

DOC’s rerating now depends less on the demographic narrative than on whether improved FFO converts into durable same-store NOI and lower leverage. After a sharp year-to-date move, the forward yield is no longer a sufficient valuation anchor: if Treasury yields remain elevated, DOC must demonstrate that rent growth, occupancy, and development yields can outpace refinancing costs. The key near-term read-through is its cost of capital versus private-market healthcare real-estate cap rates; narrowing that spread would support external growth, while a wider spread limits accretive acquisitions.

The less obvious beneficiary is O: higher-quality, long-duration net-lease cash flows can become a relative refuge if healthcare-property fundamentals prove more cyclical than expected. Conversely, DOC’s laboratory and outpatient exposure has tenant-concentration and biotech-funding sensitivity that a broad “aging population” thesis obscures; weakness in life-sciences leasing would pressure occupancy and leasing-cost assumptions before it materially affects reported FFO.

For the next 1-3 months, rate volatility is likely more important than another modest guidance increase. A falling 10-year Treasury yield can expand healthcare-REIT multiples quickly, but a renewed rise in real yields would likely compress DOC’s multiple despite operating execution. Over 6-18 months, the thesis is validated only if same-store cash NOI stays positive, leasing spreads remain constructive, and net debt/EBITDA declines rather than relying on asset sales or equity issuance.

Key Decisions for Investors

• Do not chase DOC after the post-earnings rerating; accumulate only on rate-driven weakness, preferably below a level implying a meaningful discount to its healthcare-REIT peer valuation. Target a 6-12 month total-return profile of 10-15%; exit if next-quarter FFO guidance is cut or same-store NOI turns negative.
• Use a relative-value expression: long DOC / short O only if 10-year Treasury yields decline by at least 25-35 bps and DOC’s leasing metrics improve. DOC offers greater operating upside in that regime; O is the hedge against a renewed yield backup. Reassess if the spread moves 10% against entry.
• Maintain O as the defensive alternative rather than treating it as a direct negative read-through. If real yields rise, favor O over DOC because its more diversified, contractual rent base should carry lower leasing and development-risk volatility.
• Set an earnings watchlist for DOC: occupancy, cash same-store NOI, leasing spreads, development funding commitments, interest expense, and net debt/EBITDA. An FFO beat without improvement in these inputs is not sufficient confirmation for a larger long.